Law Offices of Howard G. Smith announces an investigation on behalf of Helius Medical Technologies, Inc. investors (Helius or the Company) (NASDAQ: HSDT) concerning the Company and its officers possible violations of federal securities laws.
On April 10, 2019, Helius announced that the U.S. Food and Drug Administration (FDA) declined the Companys request for De Novo classification and 510(k) clearance of the Companys Portable Neuromodulation Stimulator (PoNS„¢) device.
On this news, shares of Helius fell nearly 66% on April 10, 2019, thereby injuring investors.
If you purchased Helius securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.